Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.
Dhingra
H M
HM
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Murphy
W K
WK
Winn
R J
RJ
Raber
M N
MN
Hong
W K
WK
D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; C013938:5,6-dihydro-5-azacytidine; D001374:Azacitidine